Leadgene Biomedical has successfully acquired 100% equity in SIDSCO.
This strategic move is designed to integrate the operations of both companies, enhance synergies, and accelerate innovation and growth within the biotechnology sector.
Established in 2018, SIDSCO is a leading preclinical contract research organization (CRO) offering end-to-end services, including experimental design, material preparation, experiment execution, and report writing.
In 2020, the company began operations in the Luzhu District of the Southern Taiwan Science Park, achieving TAF-certified GLP compliance registration in 2022, enabling the execution of GLP-compliant studies.
Post-acquisition, Leadgene Biomedical and SIDSCO will collaborate on deep business integration, combining their strengths in diagnostic reagent development, manufacturing, and preclinical trial services. This partnership aims to deliver a more comprehensive and integrated biotechnology value chain to clients.
Dr. Yung-Chun Chuang, Chairman of Leadgene Biomedical, commented, “This acquisition allows us to merge the expertise and resources of both companies to build a stronger biotechnology platform.
Our vision is to provide clients with seamless, turnkey solutions from research and development to preclinical trials, fostering the advancement of Taiwan’s biotechnology industry.”
